ROCKVILLE, Md. , June 26, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that earlier today it sued generic drug maker Apotex

Creates leading CNS portfolio with five marketed products, two product candidates in late-stage development, and robust pipeline ROCKVILLE, Md. , June 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing

ROCKVILLE, Md. , May 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present an

ROCKVILLE, Md. , May 15, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that on May 14, 2020 the Company received

First quarter total revenue of $95.0 million , an 11% increase over 2019 First quarter net product sales of $92.5 million , an 11% increase over 2019 First quarter operating earnings of $29.0 million , a 14% increase over 2019 On track for launch of SPN-812 at the end of 2020, pending FDA approval.

  Expands and strengthens neurology portfolio with three marketed CNS products and late-stage pipeline Diversifies revenue and operating cash flow base with 2019 net sales of approximately $150 million and operating earnings of $45 million Enhances long term growth with po tential launch of

ROCKVILLE, Md. , April 24, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business

Companies to Collaborate on Phase II Development for NV-5138 in Depression NV-5138 is a Novel First-in-Class Activator of mTORC1 Supernus Receives Exclusive Option to License or Acquire NV -5138 Prior to Initiation of Phase III Clinical Program ROCKVILLE, Md. and CAMBRIDGE, Mass.

ROCKVILLE, Md. , March 30, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today provides a business update related to the COVID-19

ROCKVILLE, Md. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present an